Mereo BioPharma treatment granted PRIME designation by EMA
Mereo Biopharma Group Ltd
€3.46
19:59 22/03/17
0.61%
€0.02
Clinical stage biopharmaceutical company Mereo BioPharma Group announced on Monday that the the European Medicines Agency has granted BPS-804 ‘PRIority MEdicines’ (PRIME) designation for the treatment of osteogenesis imperfecta (OI), or ‘brittle bone disease’.